Palvella Therapeutics to expand Phase 3 SELVA trial to include younger patients

Palvella Therapeutics (PVLA) announced that it will expand SELVA, the Company’s Phase 3 clinical trial of QTORIN 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations, to include patients ages 3 to 5 years old. Previously, trial participants were required to be at least 6 years old. This decision follows communication with the U.S. Food and Drug Administration in which the agency deemed the Company’s proposed expansion acceptable.